HR Execs on the Move

Lumos Diagnostics

www.lumosdiagnostics.com

 
Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

R2 Technology

R2 Technology, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Oregon Bioscience

Oregon Bioscience Association (@OregonBio) members are involved in cutting edge research and development of innovative health care, agricultural and environmental bio technologies. Our corporate members range from entrepreneurial start ups developing a first product to large multinationals. We also represent the state`s biotech research institutions, service providers to the industry and academic centers of learning. A unified voice for the Oregon bioscience community the Oregon Bio: * Represents the bioscience research to commercialization process * Helps to accelerate the growth of the biosciences industry in all parts of Oregon * Enhances the state`s bioscience business and research climate * Helps attract and retain bioscience talent and companies. * Vigorously works to improve the quality of the bioscience workforce * Partners with government at all levels to achieve its goals.

BioMedix

Previously Mr. Lerner has served as Vice President of Engineering and Technology for both Image Sensing Systems, Inc. and Telex Communications, Inc.

pangenex

pangenex is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Replimune

Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.